InpharmD™





One touch literature search.

So you can spend more time with patients →

Ask any clinical question, receive a curated response.

Get Started Free

Trusted by 10,000+ clinical pharmacists.

                           

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?

Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


134,938

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

Is there any probiotic that is clinically relevant in treating or preventing C. Diff?
What efficacy and safety literature is there for use of tirofiban in non-cardioembolic stroke?
Please summarize clinical trials and national literature surrounding the following agents: olezarsen, eplontersen, gi...
Please compare and contrast clinical information regarding the use of nebulized 0.9%, 3%, and 7% sodium chloride inha...
What are therapeutic alternatives to inhaled epoprostenol for ARDS/hypoxia during shortage? Also need therapeutic alt...

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:azkaa@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Due to the absence of supportive data and heterogeneity of specific probiotic products available, none are particularly recommended for treating or preventing C. difficile. The 2021 American College of Gastroenterology (ACG) guidelines recommend against probiotics for the prevention of Clostridioides difficile infection (CDI) in patients being treated with antibiotics (primary prevention) and for the prevention of CDI recurrence (secondary prevention). While the 2021 Infectious Diseases Socie...

In the setting of Clostridioides difficile infection (CDI), the 2021 American College of Gastroenterology (ACG) guidelines recommend against probiotics for the prevention of CDI in patients being treated with antibiotics (primary prevention) and for the prevention of CDI recurrence (secondary prevention). Since probiotics are marketed as dietary supplements without strict oversight by the U.S. Food and Drug Administration required for drugs, the evidence for the use of probiotics is generally limited. Hence, manufacturers have little incentive to conduct clinical trials to support specific indications. Additionally, data based on case reports revealed several risks associated with the use of probiotics including bloodstream infections in critically ill patients. Microbiome analyses have also observed probiotics to impede normal recolonization of the colon after antibiotic courses. Evidence to support probiotics for CDI comes primarily from meta-analyses that pooled data from small t...

READ MORE→

A search of the published medical literature revealed 2 studies investigating the researchable question:

Is there any probiotic that is clinically relevant in treating or preventing C. Diff?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections [published correction appears in Am J Gastroenterol. 2022 Feb 1;117(2):358]. Am J Gastroenterol. 2021;116(6):1124-1147. doi:10.14309/ajg.0000000000001278
[2] Allen SJ, Wareham K, Wang D, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomized, double-blind, placebo-controlled, multicentre trial. Lancet. 2013;382(9900):1249-1257. doi:10.1016/S0140-6736(13)61218-0
[3] Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12(12):CD006095. Published 2017 Dec 19. doi:10.1002/14651858.CD006095.pub4
[4] McFarland LV, Ship N, Auclair J, Millette M. Primary prevention of Clostridium difficile infections with a specific probiotic combining Lactobacillus acidophilus, L. casei, and L. rhamnosus strains: assessing the evidence. J Hosp Infect. 2018;99(4):443-452. doi:10.1016/j.jhin.2018.04.017
[5] Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010;105(7):1636-1641. doi:10.1038/ajg.2010.11
[6] Shen NT, Maw A, Tmanova LL, et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017;152(8):1889-1900.e9. doi:10.1053/j.gastro.2017.02.003
[7] Esmaeilinezhad Z, Ghosh NR, Walsh CM, et al. Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2025;9(9):CD006095. Published 2025 Sep 11. doi:10.1002/14651858.CD006095.pub5
[8] Barker AK, Duster M, Valentine S, et al. A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO). J Antimicrob Chemother. 2017;72(11):3177-3180. doi:10.1093/jac/dkx254
[9] Ma Y, Yang JY, Peng X, Xiao KY, Xu Q, Wang C. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. J Dig Dis. 2020;21(2):69-80. doi:10.1111/1751-2980.12839
[10] Li Z, Zhu G, Li C, Lai H, Liu X, Zhang L. Which Probiotic Is the Most Effective for Treating Acute Diarrhea in Children? A Bayesian Network Meta-Analysis of Randomized Controlled Trials. Nutrients. 2021;13(12):4319. Published 2021 Nov 29. doi:10.3390/nu13124319
[11] Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029-e1044. doi:10.1093/cid/ciab549
[12] McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085
[13] Su GL, Ko CW, Bercik P, et al. AGA Clinical Practice Guidelines on the Role of Probiotics in the Management of Gastrointestinal Disorders. Gastroenterology. 2020;159(2):697-705. doi:10.1053/j.gastro.2020.05.059
[14] Guarner F, Sanders ME, Szajewska H, et al. World Gastroenterology Organisation Global Guidelines: probiotics and prebiotics. Published February 2023. Accessed March 3, 2026. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pdf
InpharmD's Answer GPT's Answer

Author:Dena Homayounieh, PharmD, BCPS + InpharmD™ AI LEARN MORE 

The latest AHA/ASA guidelines do not recommend intravenous tirofiban for non-cardioembolic stroke; however, limited emerging evidence suggests it may improve short-term neurological function and 90-day outcomes when administered intravenously or intra-arterially, alone or with low-dose rt-PA, without a meaningful increase in symptomatic intracranial hemorrhage or mortality. While promising, these findings are constrained by small sample sizes, heterogeneous patient populations, and variable d...

According to the 2026 American Heart Association/American Stroke Association (AHA/ASA) Guideline for the Early Management of Patients With Acute Ischemic Stroke, the efficacy of intravenous (IV) tirofiban to improve clinical outcomes in patients with acute ischemic stroke (AIS) is not well established. Although early indications suggest that IV tirofiban may enhance recanalization rates when used with intravenous thrombolysis (IVT), definitive data on long-term safety and functional benefits remain limited. Additional research is needed to determine optimal patient selection, such as those with large-vessel occlusion (LVO) or who are undergoing bridging therapies, to establish dosing regimens, and to clarify the interplay of tirofiban’s platelet inhibition with thrombolytics to mitigate hemorrhagic risk. Ongoing large multicenter trials aim to validate these preliminary safety findings, define net clinical benefit, and refine treatment protocols. In contrast, for patients with nonca...

READ MORE→

A search of the published medical literature revealed 5 studies investigating the researchable question:

What efficacy and safety literature is there for use of tirofiban in non-cardioembolic stroke?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Prabhakaran S, Gonzalez NR, Zachrison KS, et al. 2026 guideline for the early management of patients with acute ischemic stroke: a guideline from the american heart association/american stroke association. Stroke. Published online January 26, 2026:STR.0000000000000513. doi:10.1161/STR.0000000000000513
[2] de Almeida Monteiro G, Leite M, Gonçalves OR, et al. Efficacy and safety of intravenous tirofiban combined with reperfusion therapy versus reperfusion therapy alone in acute ischemic stroke: a meta-analysis of randomized controlled trials. J Thromb Thrombolysis. 2025;58(4):526-537. doi:10.1007/s11239-025-03094-2
[3] Gong J, Shang J, Yu H, et al. Tirofiban for acute ischemic stroke: systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76(4):475-481. doi:10.1007/s00228-019-02817-8
[4] Qiu L, Xiong M, Li X, Xu L, Li Z, Ouyang P. Efficacy and safety of intra-arterial tirofiban in acute ischemic stroke without large-vessel occlusion. Neuro Endocrinol Lett. Published online December 29, 2025.
[5] Clinicaltrials.gov. Tirofiban for Patients With intraCranial Artery Stenosis and High-risk Acute Non-disabling Cerebrovascular Events (CHANCE-4). Updated July 12, 2024. Accessed March 5, 2026. https://clinicaltrials.gov/study/NCT06319846

InpharmD's Answer GPT's Answer

Author:azkaa@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Clinical trials and national literature report on several agents including olezarsen, eplontersen, givinostat, vutrisiran, and nedosiran for rare genetic and metabolic disorders. Studies of olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III (APOC3), report significant triglyceride lowering in patients with severe hypertriglyceridemia and familial chylomicronemia syndrome. Evidence supports the use of eplontersen for adults with hereditary transthyretin-related amyloidosis ...

Eplontersen According to NICE's 2024 technology appraisal guidance (TA1020), eplontersen has been recommended as an option for treating hereditary transthyretin-related amyloidosis in adults with stage 1 or stage 2 polyneuropathy. This guidance was concluded after evaluating eplontersen's efficacy in comparison to existing treatments such as vutrisiran, which is currently a usual treatment for the condition. Eplontersen offers the convenience of self-administration at home with a monthly injection, whereas vutrisiran requires administration every three months. Evidence from clinical trials indicated that eplontersen is more effective than placebo in reducing transthyretin levels and delaying the progression of polyneuropathy. While direct comparisons between eplontersen and vutrisiran in clinical trials are unavailable, indirect evidence suggests comparable efficacy between the two treatments. The 2024 guidance also includes a cost analysis, which demonstrates that eplontersen pr...

READ MORE→

A search of the published medical literature revealed 0 studies investigating the researchable question:

Please summarize clinical trials and national literature surrounding the following agents: olezarsen, eplontersen, givinostat, vutrisiran, nedosiran.

READ MORE→

[1] National Institute for Health and Care Excellence. Eplontersen for treating hereditary transthyretin-related amyloidosis: technology appraisal guidance TA1020 – recommendations. Published November 27, 2024. Accessed March 5, 2026. https://www.nice.org.uk/guidance/ta1020/chapter/1-Recommendations
[2] Michelle M. Kittleson, Amrut V. Ambardekar, Richard K. Cheng, Jan M. Griffin, Mathew S. Maurer, Jose Nativi‑Nicolau, Frederick L. Ruberg, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. Journal of the American College of Cardiology. 2026;87(5):549-565. doi:10.1016/j.jacc.2025.09.004.
[3] Bergmark BA, Marston NA, Prohaska TA, et al. Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk. N Engl J Med. 2024;390(19):1770-1780. doi:10.1056/NEJMoa2402309
[4] Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome. N Engl J Med. 2024;390(19):1781-1792. doi:10.1056/NEJMoa2400201
[5] Marston NA, Bergmark BA, Alexander VJ, et al. Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk. N Engl J Med. 2026;394(5):429-441. doi:10.1056/NEJMoa2512761
[6] Conceição I, Berk JL, Weiler M, et al. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform. J Neurol. 2024;271(10):6655-6666. doi:10.1007/s00415-024-12616-6
[7] Wixner J, Berk JL, Adams D, et al. Effects of eplontersen on symptoms of autonomic neuropathy in hereditary transthyretin-mediated amyloidosis: secondary analysis from the NEURO-TTRansform trial. Amyloid. 2025;32(1):29-38. doi:10.1080/13506129.2024.2427290
[8] Masri A, Maurer MS, Claggett BL, et al. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis. J Card Fail. 2024;30(8):973-980. doi:10.1016/j.cardfail.2023.11.016
[9] Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2024;23(4):393-403. doi:10.1016/S1474-4422(24)00036-X
[10] Finazzi G, Vannucchi AM, Martinelli V, et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br J Haematol. 2013;161(5):688-694. doi:10.1111/bjh.12332
[11] Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025;392(1):33-44. doi:10.1056/NEJMoa2409134
[12] Adams D, Tournev IL, Taylor MS, et al. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid. 2023;30(1):1-9. doi:10.1080/13506129.2022.2091985
[13] Jering KS, Fontana M, Skali H, et al. Effects of Vutrisiran on Cardiac Function and Outcomes in Patients With Transthyretin Amyloidosis With Cardiomyopathy. J Am Coll Cardiol. 2025;86(6):444-455. doi:10.1016/j.jacc.2025.06.022
[14] Hoppe B, Koch A, Cochat P, et al. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 2022;101(3):626-634. doi:10.1016/j.kint.2021.08.015
[15] Baum MA, Langman C, Cochat P, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2023;103(1):207-217. doi:10.1016/j.kint.2022.07.025

InpharmD's Answer GPT's Answer

Author:Dena Homayounieh, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Clinical evidence evaluating nebulized sodium chloride inhalation solutions indicates differing roles for isotonic (0.9%) and hypertonic (≥3%) concentrations across respiratory conditions. In bronchiolitis, 0.9% saline is commonly used as a control comparator, while hypertonic saline, most frequently 3%, has demonstrated modest improvements in clinical severity scores and small reductions in hospital length of stay or hospitalization risk in some analyses, although findings across trials are ...

A 2014 clinical practice guideline evaluated evidence regarding therapies for bronchiolitis in infants aged 1 to 23 months, including nebulized sodium chloride solutions of varying concentrations. The guideline notes that most clinical trials investigating nebulized saline for bronchiolitis have used 3% hypertonic saline, while 0.9% sodium chloride (normal saline) is typically used as a comparator or placebo in randomized studies. Evidence summarized in the guideline indicates that nebulized hypertonic saline (primarily 3%) may improve clinical symptom scores after approximately 24 hours of treatment and may reduce hospital length of stay in settings where the average hospitalization exceeds three days; however, findings across randomized controlled trials are inconsistent. Consequently, the guideline recommends that nebulized hypertonic saline not be administered in the emergency department (moderate recommendation) but states that clinicians may administer nebulized hypertonic sal...

READ MORE→

A search of the published medical literature revealed 1 study investigating the researchable question:

Please compare and contrast clinical information regarding the use of nebulized 0.9%, 3%, and 7% sodium chloride inhalation solution.

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Ralston SL, Lieberthal AS, Meissner HC, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–e1502. doi:10.1542/peds.2014-2742.
[2] Zhang L, Mendoza-Sassi RA, Wainwright CE, Aregbesola A, Klassen TP. Nebulised hypertonic saline solution for acute bronchiolitis in infants. Cochrane Acute Respiratory Infections Group, ed. Cochrane Database of Systematic Reviews. 2023;2023(4). doi:10.1002/14651858.CD006458.pub5
[3] Yu JF, Zhang Y, Liu ZB, Wang J, Bai LP. 3% nebulized hypertonic saline versus normal saline for infants with acute bronchiolitis: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2022;101(43):e31270. doi:10.1097/MD.0000000000031270.
[4] Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2018;9(9):CD001506. Published 2018 Sep 27. doi:10.1002/14651858.CD001506.pub4
[5] Tarrant BJ, Maitre CL, Romero L, et al. Mucoactive agents for adults with acute lung conditions: A systematic review. Heart & Lung. 2019;48(2):141-147. doi:10.1016/j.hrtlng.2018.09.010
[6] Zhang L, Mendoza-Sassi RA, Klassen TP, Wainwright C. Nebulized Hypertonic Saline for Acute Bronchiolitis: A Systematic Review. Pediatrics. 2015;136(4):687-701. doi:10.1542/peds.2015-1914
[7] Tarrant BJ, Le Maitre C, Romero L, et al. Mucoactive agents for chronic, non-cystic fibrosis lung disease: A systematic review and meta-analysis. Respirology. 2017;22(6):1084-1092. doi:10.1111/resp.13047

InpharmD's Answer GPT's Answer

Author:Dena Homayounieh, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Inhaled epoprostenol has been compared to inhaled iloprost, trepostinil, and commonly, inhaled nitric oxide. For pulmonary arterial hypertension, overall data suggests comparable efficacy and safety between the agents. Similarly, for ARDS, efficacy and safety was also comparable between epoprostenol and inhaled nitric oxide. Notably, selection of agents may be greatly influenced by availability and cost.

A 2015 review discussed the role of inhaled prostacyclin as a treatment for ARDS. Overall, there appears to be a lack of robust evidence on selective pulmonary vasodilators (SPVs), a class that includes inhaled prostacyclins, and their use in ARDS management. A referenced 1996 prospective crossover trial (N=8) compared iEPO and iNO in mechanically ventilated ARDS patients with pulmonary hypertension (PAP ≥30 mm Hg), using escalating doses of each agent. Both reduced PAP dose-dependently; iEPO lowered mean PAP from 35.1 to 29.6 mm Hg and PVR without systemic effects, while improving PaO₂/FiO₂ at 10 and 25 ng/kg/min. iNO produced more consistent oxygenation gains (PaO₂ from 116 ± 47 to 167 ± 86 mm Hg at 8 ppm) and reduced shunt, though it had limited PVR impact. Individual responses varied, with iEPO benefiting some iNO non-responders. Another referenced 1996 randomized crossover study (N=16) in severe ARDS showed both agents improved PaO₂/FiO₂ (by 29 mm Hg with iNO, 21 mm Hg with iEP...

READ MORE→

A search of the published medical literature revealed 7 studies investigating the researchable question:

What are therapeutic alternatives to inhaled epoprostenol for ARDS/hypoxia and PAH during shortage?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Searcy RJ, Morales JR, Ferreira JA, Johnson DW. The role of inhaled prostacyclin in treating acute respiratory distress syndrome. Ther Adv Respir Dis. 2015;9(6):302-312. doi:10.1177/1753465815599345
[2] Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1671-1677. doi:10.1164/ajrccm.154.6.8970353
[3] Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153(3):991-996. doi:10.1164/ajrccm.153.3.8630585
[4] Bosch NA, Law AC, Vail EA, et al. Inhaled Nitric Oxide vs Epoprostenol During Acute Respiratory Failure: An Observational Target Trial Emulation. Chest. 2022;162(6):1287-1296. doi:10.1016/j.chest.2022.08.001
[5] Chen SH, Chen LK, Teng TH, Chou WH. Comparison of inhaled nitric oxide with aerosolized prostacyclin or analogues for the postoperative management of pulmonary hypertension: a systematic review and meta-analysis. Ann Med. 2020;52(3-4):120-130. doi:10.1080/07853890.2020.1746826
[6] Buckley MS, Agarwal SK, Garcia-Orr R, Saggar R, MacLaren R. Comparison of Fixed-Dose Inhaled Epoprostenol and Inhaled Nitric Oxide for Acute Respiratory Distress Syndrome in Critically Ill Adults. J Intensive Care Med. 2021;36(4):466-476. doi:10.1177/0885066620906800

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


—   Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


—   Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


—   Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free